sponsored
PatientsVille.com Logo

PatientsVille

Hyperhidrosis Medical Research Studies

Up-to-date List of Hyperhidrosis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Hyperhidrosis Medical Research Studies

Rank Status Study
1 Not yet recruiting Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
Condition: Hyperhidrosis
Interventions: Drug: Botox (onabotulinumtoxinA);   Drug: NeuroBloc/Myobloc (rimabotulinumtoxinB);   Drug: NaCl (placebo)
Outcome Measures: DLQI (Dermatology Life Quality Index);   AE (Adverse Events);   Gravimetry;   HDSS (Hyperhidrosis Disease Severity Scale);   Health outcome (EQ-5D);   LSAS-SR (Liebowitz Social Anxiety Scale-Self Report);   MADRS-S (Montgomery-Asberg Depression Rating Scale-Self report);   Global Assessment of Therapy
2 Not yet recruiting Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis
Condition: Primary Hyperidrosis
Interventions: Drug: Oxybutynin;   Drug: Placebo
Outcome Measures: Oxybutynin Chloride efficacy;   Perception of improvement;   Evaluate therapeutic safety;   Quality of life;   Time of subject response;   Duration of response;   Evaluation between quality of life and groups
3 Recruiting Histological Analysis Following Ulthera System Treatment for Hyperhidrosis
Condition: Hyperhidrosis
Intervention: Device: Ulthera System Treatment
Outcome Measures: Reduction in the number of sweat glands from baseline to 90-days post-treatment.;   Reduction in spontaneous axillary sweat production assessed by gravimetric method at 90-days post treatment;   HDSS score reduction;   Starch iodine test
4 Recruiting Tx Axillary Hyperhidrosis 1210nm Diode Laser
Condition: Axillary Hyperhidrosis
Intervention: Device: 1210nm Diode Laser treatments
Outcome Measures: subjective global assessment questionnaire;   gravimetric analysis;   modified starch-iodine test
5 Recruiting Comparator Study of the Effect of DRM04B and DRM 04 in Subjects With Axillary Hyperhidrosis
Condition: Hyperhidrosis
Interventions: Drug: Dose 1 of DRM04B;   Drug: Dose 2 of DRM04B;   Drug: Dose 1 of DRM04;   Drug: Dose 2 of DRM04;   Other: Vehicle
Outcome Measures: Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 4;   Proportion of subjects who have a minimum 2-grade improvement in HDSS from Baseline at Week 4;   Absolute change in the gravimetrically measured sweat production from Baseline to Week 4;   Absolute change in the gravimetrically measured sweat production from Baseline to Week 6;   Proportion of subjects who have a minimum 1-grade improvement in HDSS from Baseline at Week 6
6 Recruiting A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
Condition: Hyperhidrosis
Intervention: Drug: BBI-4000
Outcome Measures: Percent change in the gravimetrically measured sweat production from baseline;   Absolute change in the gravimetrically measured sweat production from baseline;   Proportion of subjects who have a minimum of 2-grade improvement in HDSS from baseline.;   Proportion of subjects who have a minimum of 1-grade improvement in HDSS from baseline
7 Recruiting Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
Condition: Hyperhidrosis
Intervention: Drug: [14C]Umeclidinium 18.5 mg
Outcome Measures: PK Assessment (Cmax) for [14C] umeclidinium and total radioactivity;   PK Assessment (tmax) for [14C] umeclidinium and total radioactivity;   PK Assessment (AUC) for [14C] umeclidinium and total radioactivity;   PK Assessment (t1/2) for [14C] umeclidinium and total radioactivity;   Compartmental modeling of absorption rate for [14C] umeclidinium;   Compartmental modeling of elimination rate for [14C] umeclidinium;   Determine the amount of Umeclidinium absorbed in the skin;   Safety Assessment for AEs;   Safety Assessment for ECGs, and telemetry;   Safety Assessment for hematology laboratory parameters;   Safety Assessment for measurement of blood pressure;   Number of subjects with application site skin irritation;   Safety Assessment for clinical chemistry laboratory parameters;   Safety Assessment for measurement of pulse rate
8 Recruiting Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G)
Conditions: Hyperhydrosis;   Depression
Intervention: Drug: Glycopyrrolate
Outcome Measures: Clinical Global Impression- Improvement scores;   change in mean of patient rated severity of sweating for each week, and change in mean skin conductance for each week
9 Recruiting Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating
Condition: Menopausal Hot Flushes
Intervention: Drug: Sage extract, 3400 mg , DER 1:17
Outcome Measures: Change from Baseline Hyperhidrosis Disease Severity Scale;   Change from Baseline Menopause Rating Scale / MRS;   Change from Baseline Modified Dem Tect
10 Recruiting Comparison of Methods of Lumbar Sympathetic Ganglion Block: Distance vs Angle
Condition: Lumbar Sympathetic Ganglion Block Indication: Neuropathic Pain, CRPS, Hyperhydrosis Etc.
Intervention: Procedure: lumbar sympathetic ganglion block
Outcome Measures: temperature change;   muscle or vessel shadow
11 Not yet recruiting ASIS for Enbrel in Plaque Psoriasis
Condition: Plaque Psoriasis.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Enbrel subcutaneously at Week 12;   Drug: Efficacy of Enbrel subcutaneously at Week 24;   Drug: Efficacy of Enbrel subcutaneously at Week 36;   Drug: Efficacy of Enbrel subdermally at Week 12;   Drug: Efficacy of Enbrel subdermally at Week 24;   Drug: Efficacy of Enbrel subdermally at Week 36;   Drug: PASI 75 n(%) subcutaneously at Week 12;   Drug: PASI 75 n(%) subcutaneously at Week 24;   Drug: PASI 75 n(%) subcutaneously at Week 36;   Drug: PASI 75 n(%) subdermally at Week 12;   Drug: PASI 75 n(%) subdermally at Week 24;   Drug: PASI 75 n(%) subdermally at Week 36;   Drug: Adverse Reactions of Enbrel subcutaneously;   Drug: Adverse Reactions of Enbrel subdermally at Week 36
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Enbrel subcutaneously vs. subdermally in Plaque Psoriasis.
12 Unknown  Inherited Myokymia: A Clinical and Genetic Study of a Family
Condition: A Study of Clinical and Genetic Mutations in a Family of Neuromyotonia, so Called Isaac's Syndrome
Intervention:
Outcome Measure:
13 Not yet recruiting Single-port Thoracoscopic Sympathicotomy in Complex Regional Pain Syndrome Type I (CRPS)
Condition: Complex Regional Pain Syndrome Type I of the Upper Limb
Intervention: Procedure: unilateral single-port VATS sympathicotomy
Outcome Measures: Change in perceived pain measured in Visual Analogue Scale;   Change in function in extremity

These studies may lead to new treatments and are adding insight into Hyperhidrosis etiology and treatment.

A major focus of Hyperhidrosis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Hyperhidrosis